<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043730</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002973-23</org_study_id>
    <nct_id>NCT02043730</nct_id>
  </id_info>
  <brief_title>Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.</brief_title>
  <acronym>GAP</acronym>
  <official_title>A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unit√† Sperimentazioni cliniche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Nazionale Tumori di Napoli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is the fourth cause of cancer mortality: there are different treatment
      approaches to locally advanced pancreatic cancer management.

      Generally, gemcitabine alone is considered a reasonable approach for advanced pancreatic
      cancer patients but we need a chemotherapeutic regimen able to prevent as much as possible a
      progression of the disease. Nab-paclitaxel (Abraxane) recently demonstrated an interesting
      activity profile in advanced pancreatic cancer. A combination of Nab-paclitaxel and
      gemcitabine has been demonstrated superior to gemcitabine alone in metastatic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population: Locally advanced unresectable pancreatic cancer patients

      Elegibility criteria:

        -  Written informed consent

        -  Age &gt;18 &lt; 75 years

        -  Histologically/cytologically confirmed locally advanced, unresectable pancreatic cancer

        -  At least one lesion measurable with CT or MRI scan

        -  Performance Status (ECOG) 0-1 at study entry

        -  Life expectancy of at least 3 months

        -  Adequate marrow, liver and renal function

        -  Effective contraception if the risk of conception exists (in the Informed Consent for
           the patients the descriptions of possible contraceptives is reported
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 14, 2019</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Rate</measure>
    <time_frame>progression rate is evaluated after 3 cycles of chemotherapy</time_frame>
    <description>Assuming an expected progression rate in the control arm of 40% and an auspicated progression rate in the experimental arm of 20%,with one-tailed alpha=0.05, 80% power, 124 patients are required for the final analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Response</measure>
    <time_frame>Response to treatment is evaluated according to the RECIST criteria at the end of chemotherapy</time_frame>
    <description>All patients must be considered in response analysis, including those who discontinue treatment or who die for any reason prior to response evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Esplore the effects of nab-paclitaxel in terms of toxicity</measure>
    <time_frame>every 3 cycles of chemotherapy</time_frame>
    <description>Treatment-emergent adverse events, drug-related adverse events and safety laboratory parameters will be analysed by treatment groups and CTCAE grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>time from the start of the treatment until PD or death</time_frame>
    <description>Progression free survival time will be defined as the time from randomization until the date of first observed disease progression (radiological or clinical, whichever is earlier) or death due to any cause, if death occurs before progression is documented.
Patients who did not progress will be censored at the last date they were known to be alive.
Patients who died of disease and for whom a date of progression is not available will be considered to have progressed on the day of their death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>the time from randomization to the date of death</time_frame>
    <description>Overall survival time will be defined as the time from randomization to the date of death. If the subject has not died, survival will be censored on the last date the subject was known to be alive (last date of follow up).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Pancreatic Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel and Gemcitabine</intervention_name>
    <description>Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle</description>
    <arm_group_label>nab-paclitaxel and gemcitabine</arm_group_label>
    <other_name>abraxane</other_name>
    <other_name>gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.</description>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_label>nab-paclitaxel and gemcitabine</arm_group_label>
    <other_name>gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age &gt;18 &lt; 75 years

          -  Histologically/cytologically confirmed locally advanced, unresectable pancreatic
             cancer

          -  At least one lesion measurable with CT or MRI scan

          -  Performance Status (ECOG) 0-1 at study entry

          -  Life expectancy of at least 3 months

          -  Adequate marrow, liver and renal function

          -  Effective contraception if the risk of conception exists (in the Informed Consent for
             the patients the descriptions of possible contraceptives is reported)

        Exclusion Criteria:

          -  Previous chemotherapy or radiotherapy for pancreatic cancer

          -  Severe cardiovascular disease

          -  Thrombotic or embolic events

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease

          -  Known hypersensitivity to study drug

          -  Known drugs or alcohol abuse

          -  Pregnant or breastfeeding women

          -  Previous or concurrent malignancy; except for basal or squamous cell skin cancer
             and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and
             with evidence of no recurrence for at least 5 years prior to randomization

          -  Unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Cascinu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>GISCAD Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Treviglio-Caravaggio, P.le Ospedale n1</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Humanitas Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale G.Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASDAA Bolzano</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario D.Casula</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Anna</name>
      <address>
        <city>Como</city>
        <state>CO</state>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale S.Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Polo Oncologico Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza,</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULSS15 di Camposampiero/Cittadella</name>
      <address>
        <city>Camposampiero</city>
        <state>PD</state>
        <zip>35012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Fano</city>
        <state>Pesaro</state>
        <zip>61032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaluiera Universitaria</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S.Salvatore</name>
      <address>
        <city>Pesaro</city>
        <state>PS</state>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS F.S. Maugeri</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Vigevano</city>
        <state>PV</state>
        <zip>27029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <state>PZ</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile degli Infermi</name>
      <address>
        <city>Faenza</city>
        <state>Ravenna</state>
        <zip>48014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Lugo</city>
        <state>Ravenna</state>
        <zip>48022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S.Maria Nuova - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. C√† Foncello</name>
      <address>
        <city>Treviso</city>
        <state>TV</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo</name>
      <address>
        <city>Busto Arsizio</city>
        <state>Varese</state>
        <zip>21051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura di Poliambulanza, Via Bissolati 57</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Careggi-Universit√†, Viale Pieraccini, 17</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Universitario Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INT-IRCCS Fondazione G.Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A.Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S.Giovanni Calabita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Sondrio</name>
      <address>
        <city>Sondrio</city>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>locally advanced</keyword>
  <keyword>unresectable cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

